agonistGlucagon-like peptide-1 (GLP-1) receptor is an ideal target in the development of incretin-based therapies for diabetes and obesity. Two approaches have been adopted: GLP-1 receptor agonists that mimic the effects of native GLP-1 and dipeptidyl peptidase-4 inhibitors that increase ...
This study assessed whether treatment with the glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EXE) could prevent GC-induced glucose intolerance. A randomized, placebo-controlled, double-blind, crossover study in eight healthy men (age: 23.5 [20.0–28.3] years; BMI: 26.4 [24.3–...
with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a ... BEST,JENNIE,H.,... - 《Diabetes Care》 被引量: 340发表: 2011年 Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Di...
葡萄糖依赖性促胰岛素释放多肽受体(Glucose-dependent insulinotropic polypeptide receptor, GIPR)、胰高血糖素样肽-1受体(Glucagon-like peptide-1 receptor, GLP-1R)和胰高血糖素受体(Glucagon receptor, GCGR)是2型糖尿病和肥胖症等代谢性疾病的重要治疗靶标1。近年来,基于这三个受体开发的多重激动剂展现了优于GL...
et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012). Article CAS PubMed PubMed Central Google Scholar Psichas, A. et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion...
Caleb Alexander, MD, MS JAMA Internal Medicine Video (2:02) Association Between Newer Antidiabetic Drug Classes and Mortality in Patients With Type 2 Diabetes Key Points Question How do sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl...
Fig. 1 Main physiological actions of the dual GIP and GLP-1 agonist tirzepatide. GIP—glucose-dependent insulinotropic polypeptide; GLP-1—glucagon-like peptide-1. Despite the similarities between the two incretins, it should be pinpointed that while GIP activity is mainly pancreatic, GLP-1 ac...
peptidesprotein engineeringGlucagon-like peptide-1 (GLP-1) receptor (GLP-1R), glucagon (GCG) receptor (GCGR), and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor (GIPR), are three metabolically related peptide hormone receptors. A novel ...
GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure HHF: HF hospitalisation IRR: Incidence rate ratio PCP: Primary care practitioner PMPY: Per member per year SGLT2i: Sodium–glucose transporter-2 inhibitor T2D: Type 2 diabetes ...
GLP-1 RA: Glucagon-like peptide-1 receptor agonist HF: Heart failure HHF: HF hospitalisation IRR: Incidence rate ratio PCP: Primary care practitioner PMPY: Per member per year SGLT2i: Sodium–glucose transporter-2 inhibitor T2D: Type 2 diabetes ...